Travere Therapeutics Inc.

Travere Therapeutics Inc. a biopharmaceutical company focuses on the identification development commercialization and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058 a novel investigational human enzyme replacement candidate which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations CDG Care and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin Inc. and changed its name to Travere Therapeutics Inc. in November 2020. Travere Therapeutics Inc. was incorporated in 2008 and is headquartered in San Diego California.